Next Science Ltd (AU:NXS) has released an update.
Next Science Ltd highlights the success of its XPERIENCE™ product in two retrospective studies, where a zero percent infection rate was achieved in over 1,400 knee and hip arthroplasties, marking a significant advancement in surgical irrigation and infection control. The company emphasizes its commitment to improving patient outcomes and physician efficacy through its innovative XBIO™ technology, as it prepares for the publication of these promising results.
For further insights into AU:NXS stock, check out TipRanks’ Stock Analysis page.
